FAM
RCUS icon

Fred Alger Management’s Arcus Biosciences RCUS Stock Holding History

Fred Alger Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,758
Closed -$1.07M – 502
2025
Q4 		$1.07M Buy
+44,758
New +$913K ﹤0.01% 356
2024
Q2 		– Sell
-73,498
Closed -$1.39M – 467
2024
Q1 		$1.39M Sell
73,498
-1,689
-2% -$29.2K 0.01% 360
2023
Q4 		$1.44M Sell
75,187
-781
-1% -$12.5K 0.01% 351
2023
Q3 		$1.36M Sell
75,968
-23
-0% -$462 0.01% 349
2023
Q2 		$1.54M Sell
75,991
-1,920
-2% -$36.6K 0.01% 354
2023
Q1 		$1.42M Sell
77,911
-573,601
-88% -$11M 0.01% 368
2022
Q4 		$13.5M Buy
+651,512
New +$17.9M 0.07% 184

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fred Alger Management's RCUS Position: Q1 2026 in Review

Fred Alger Management sold out of Arcus Biosciences (RCUS) in Q1 2026, closing a stake of 44,758 shares — an estimated $1.07M sold.

Fred Alger Management first reported a position in RCUS in Q4 2022 and held it in 7 quarters. The position peaked at $13.5M in Q4 2022. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Fred Alger Management reported no remaining Arcus Biosciences position as of Q1 2026 after selling out during the quarter.
  • Fred Alger Management sold 44,758 Arcus Biosciences shares in Q1 2026, an estimated $1.07M.
  • Fred Alger Management first reported a position in Arcus Biosciences in Q4 2022 and held it in 7 quarters.
  • Fred Alger Management's Arcus Biosciences position peaked at $13.5M in Q4 2022.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.